Elanco and Aratana Therapeutics finalize deal to mergeJuly 18, 2019Elanco Animal Health has acquired Aratana Therapeutics. Structured as a stock-for-stock transaction, the deal was accepted by Aratana stockholders. "Aratana's strong position in the specialty market—with its current portfolio and pipeline—complements Elanco's field presence and capitalizes on new opportunities for key existing Elanco pet therapy brands," says Jeff Simmons, president and chief executive officer of Elanco. "This deal furthers Elanco's value-generating innovation, portfolio, and productivity (IPP) strategy, while continuing to bring great value to veterinarians and pet owners." Aratana produces Galliprant, a canine NSAID for osteoarthritis for which Elanco has had the exclusive rights to develop, manufacture, and commercialize since 2016. Aratana also contributes two additional products to Elanco's portfolio: Entyce, the only FDA-approved veterinary therapeutic to stimulate appetite in dogs, and Nocita, a long-acting local anesthetic that provides up to 72 hours of post-operative pain relief following certain surgeries in dogs and cats. Further, Aratana's research and development pipeline will contribute to Elanco's efforts to sustain the introduction of novel and innovative companion animal therapeutics. As a result of the acquisition, Elanco says it is forming a new commercial team dedicated to the veterinary specialty business into which the Aratana field force will transition. This specialty sales force will …
SPONSORED CONTENTSwitch to Triple Protection in One Monthly DoseSee the difference of triple protection with the one monthly chew. + Learn More
Fungus likely linked to freshwater turtle shell diseaseJuly 17, 2019Researchers at the University of Illinois have identified a new fungus that could be linked to ulcerative shell disease in freshwater turtles.
LifeLearn partnership supports human-animal bond researchJuly 16, 2019Research exploring the mutually beneficial health benefits of people and companion animals may soon receive a boost, thanks to a new partnership between LifeLearn Animal Health and the Human Animal Bond Research Institute (HABRI).
VetStem receives immunotherapy license from human health firmJuly 15, 2019Biopharmaceutical animal health company VetStem has partnered with Calidi Biotherapeutics, a clinical‐stage biotechnology company specializing in the stem cell-based delivery of oncolytic virus-based immunotherapies for cancer.
Sioux Falls, S.D., tops list of heartworm cities for JulyJuly 15, 2019Sioux Falls, S.D., is the number one city for heartworms in July, the Companion Animal Parasite Council (CAPC) reports.
AVMA helps veterinarians prepare clients for evacuationJuly 12, 2019As Tropical Storm Barry heads toward the Gulf Coast and areas of Louisiana face potential evacuation orders, the American Veterinary Medical Association (AVMA) has detailed items veterinarians should advise pet owners to keep on hand in case of an emergency.
Cities receive certification for pet friendlinessJuly 10, 2019Twenty-five North American cities have been included in the first-ever list of “Better Cities for Pets”-certified municipalities.
Boehringer Ingelheim brand wins international awardJuly 10, 2019Boehringer Ingelheim’s Frontline has been named “Brand of the Year” in the Animalis Edition of the World Branding Awards.
Bayer and Elanco rumored to be mergingJuly 10, 2019A significant animal health merger might be in the works between pharmaceutical company Bayer and Elanco Animal Health.
FDA approves ProHeart 12July 8, 2019The U.S. Food and Drug Administration’s (FDA’s) Center for Veterinary Medicine (CVM) has approved ProHeart 12 (moxidectin) extended release injectable suspension for dogs one year and older.
